In a hospital, a routine blood test can be a source of both clarity and delay. The results pour in, a dense grid of numbers and reference ranges. But the translation into a clinical decision still falls to a physician's eye and memory. BloodFlow, a Lisbon-based startup founded last year, is betting that a carefully integrated AI layer can speed up that translation without ever letting patient data leave the hospital's walls [Perplexity Sonar Pro Brief, 2025].
The bet on on-premise integration
For BloodFlow, the product is not just the algorithm but the integration. The company's platform connects to hospital electronic health record (EHR) systems via a plug-and-play API using the HL7 FHIR standard. It aims to provide real-time, explainable interpretations of blood panels as they are processed [Perplexity Sonar Pro Brief, 2025]. The insistence on a fully on-premise deployment is a direct response to the stringent data privacy and security requirements of European healthcare providers. The initial wedge is focused squarely on blood diagnostics. Future plans include pharmaceutical clinical trials and medical device certification [Portugal Startup News, July 2025].
Fueling a solo founder's vision
The company's trajectory so far is the story of its founder, Tiago Costa. A computer engineering graduate and former high-performance athlete with Sporting, Costa built the first version of the platform solo while finishing his degree and working full-time [The Next Big Idea, 2025]. In July 2025, he secured a €1.2 million seed round to transition from a one-person project to a funded venture. The lead investor was 3xP Global's Health Innovation Fund, a Lisbon-based private equity firm with an ESG focus [Portugal Startup News, July 2025]. The capital is earmarked for team expansion, market entry, and the costly path toward regulatory approval.
Navigating a crowded and complex field
The ambition is clear. But the path is lined with established hurdles. BloodFlow enters a competitive space populated by players like Kantesti, BloodGPT, and Hathr.ai. Success hinges on more than technical prowess. It requires navigating the slow, rigorous sales cycles of hospital procurement and building the clinical evidence necessary for trust and reimbursement.
- The regulatory mountain. Any tool intended to inform clinical decisions faces a steep climb for certification as a medical device in the EU (CE marking) or clearance from the U.S. FDA. BloodFlow's stated plans for retrospective studies are just the first step on this long road [Portugal Startup News, July 2025].
- The proof-of-value gap. While the platform promises to save physician time and boost accuracy, no hospital customers, live deployments, or clinical validation metrics have been publicly disclosed. For hospital CFOs, the return on investment must be concretely proven.
- The team build-out. Costa's technical grit is documented. Scaling a healthtech company requires a blend of regulatory, commercial, and clinical expertise that a solo founder must now recruit around him.
For the patients and clinicians BloodFlow aims to serve, the current standard of care is often a manual, time-consuming process. A physician or lab technician must review a complete blood count (CBC) or comprehensive metabolic panel. They cross-reference each flagged value against a patient's history and symptoms. They decide on the next step, all while managing a high-volume caseload. The risk is not typically error, but delay and cognitive burden in an overstretched system. BloodFlow's hypothesis is that an AI assistant, trained to recognize patterns and provide context, can alleviate that burden for a broad patient population undergoing common diagnostic workups.
The next twelve months will be about moving from prototype to pilot. The seed funding provides a runway to hire key roles in commercial and clinical affairs. It also supports securing those first referenceable hospital partnerships in Portugal or beyond. For Pulse Raman, the patient outcome is the only ledger that matters. If BloodFlow can demonstrate that its on-premise AI leads to faster, more informed decisions for even a single disease state, it will have earned its place in the clinic.
Sources
- [Perplexity Sonar Pro Brief, 2025] BloodFlow AI platform summary | https://portugalstartupnews.com/2025/07/25/bloodflow-secures-e1-2m-seed-funding-to-transform-blood-test-analysis/
- [Portugal Startup News, July 2025] BloodFlow secures €1.2M seed funding to transform blood test analysis | https://portugalstartupnews.com/2025/07/25/bloodflow-secures-e1-2m-seed-funding-to-transform-blood-test-analysis/
- [The Next Big Idea, 2025] BloodFlow fecha ronda seed de 1,2 milhões para levar IA às análises de sangue | https://thenextbigidea.pt/bloodflow-fecha-ronda-seed-de-12-milhoes-para-levar-ia-as-analises-de-sangue/
- [3xP Global, July 2025] 3xP Global Invests in BloodFlow to Advance Real-Time Diagnostic Insights | https://www.3xpglobal.eu/news/3xp-global-invests-in-bloodflow